Bing-Kun Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bing-Kun Chen has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Bihui Cao
Guangdong Provincial People's Hospital
1 shared publication - Chi Zhang
KingMed School of Laboratory Medicine, Guangzhou Medical University
1 shared publication - Jian-Yu Cai
Scientific Research Center, Guangzhou Medical University
1 shared publication - Man-Ting Liu
Department of Radiology, Central Laboratory, the Second Affiliated Hospital, Guangzhou Medical University
1 shared publication - Mei-Lan Liu
The Third Clinical School of Guangzhou Medical University
1 shared publication - Wei Cheng
Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Science, Guangzhou Medical University
1 shared publication
Latest Publications
- Open Access
- 12 August 2026
- Published by Global Consulting INC in Cancer Biome and Targeted Therapy
- p. 188-221
Reprogramming CAR-T Cell Therapy for Solid Tumors: Combination Strategies to Overcome Resistance
Chimeric antigen receptor T (CAR-T) cell therapy has achieved unprecedented clinical success in hematologic malignancies, yet translating these outcomes to solid tumors has proven substantially more challenging. Unlike blood cancers, solid tumors present multiple interconnected barriers, including antigen heterogeneity, inefficient trafficking and infiltration, physical stromal constraints, metabolic competition, and profoundly immunosuppressive tumor microenvironments that collectively limit CAR-T cell persistence and function. Increasing evidence indicates that no single engineering modification is sufficient to overcome these obstacles, driving the development of combination strategies that integrate CAR-T cells with immune checkpoint blockade, cytokine and chemokine modulation, targeted therapies, radiotherapy, oncolytic viruses, cancer vaccines, biomaterial-based delivery platforms, and next-generation synthetic biology approaches. Concurrent advances in armored CAR-T cells, logic-gated circuits, multi-antigen targeting systems, and non-viral gene engineering are enabling more precise, adaptable, and controllable cellular therapies. In this review, we examine the biological mechanisms underlying resistance to CAR-T therapy in solid tumors and critically evaluate emerging combination strategies designed to enhance tumor recognition, trafficking, persistence, and antitumor activity. We further discuss translational challenges, including manufacturing complexity, toxicity management, and patient selection, and propose a framework for developing precision combination CAR-T therapies tailored to the unique biology of individual tumors. Collectively, these advances are reshaping CAR-T cell therapy from a single-agent cellular intervention into a programmable, increasingly integrated platform for solid-tumor immunotherapy.
- 12 August 2026
- Published by Global Consulting INC in Cancer Biome and Targeted Therapy
- p. 188-221
Open AccessReprogramming CAR-T Cell Therapy for Solid Tumors: Combination Strategies to Overcome Resistance
Chimeric antigen receptor T (CAR-T) cell therapy has achieved unprecedented clinical success in hematologic malignancies, yet translating these outcomes to solid tumors has proven substantially more challenging. Unlike blood cancers, solid tumors present multiple interconnected barriers, including antigen heterogeneity, inefficient trafficking and infiltration, physical stromal constraints, metabolic competition, and profoundly immunosuppressive tumor microenvironments that collectively limit CAR-T cell persistence and function. Increasing evidence indicates that no single engineering modification is sufficient to overcome these obstacles, driving the development of combination strategies that integrate CAR-T cells with immune checkpoint blockade, cytokine and chemokine modulation, targeted therapies, radiotherapy, oncolytic viruses, cancer vaccines, biomaterial-based delivery platforms, and next-generation synthetic biology approaches. Concurrent advances in armored CAR-T cells, logic-gated circuits, multi-antigen targeting systems, and non-viral gene engineering are enabling more precise, adaptable, and controllable cellular therapies. In this review, we examine the biological mechanisms underlying resistance to CAR-T therapy in solid tumors and critically evaluate emerging combination strategies designed to enhance tumor recognition, trafficking, persistence, and antitumor activity. We further discuss translational challenges, including manufacturing complexity, toxicity management, and patient selection, and propose a framework for developing precision combination CAR-T therapies tailored to the unique biology of individual tumors. Collectively, these advances are reshaping CAR-T cell therapy from a single-agent cellular intervention into a programmable, increasingly integrated platform for solid-tumor immunotherapy.